Limited efficacy of HDM201 (siremadlin) in combination with ribociclib (a CDK4/6 inhibitor) was observed in patients with locally advanced or metastatic liposarcoma, even though this tumor highly expresses MDM2 and CDK4 (55). Here, MDM2 is linked to neoplasm.